<DOC>
	<DOC>NCT01101061</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and potential immune response of AMG 785 following single subcutaneous (SC, injection under the skin) dose administration in healthy postmenopausal Japanese women.</brief_summary>
	<brief_title>A Single-dose Study Evaluating AMG 785 in Healthy Postmenopausal Japanese Women</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<criteria>Japanese subjects must be first (4 grandparents, biologic parents and subject born in Japan), second (4 grandparents and biological parents born in Japan) or third (4 grandparents born in Japan) generation Japanese Body mass index ≤ 25 kg/m2, inclusive at screening Postmenopausal females defined as 12 continuous months of spontaneous amenorrhea confirmed by a serum folliclestimulating hormone (FSH) result &gt; 40mIU/mL, or 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy) as documented in medical history (verified with an operative note, if available) Osteoporosis, as defined by bone mineral density (BMD) Tscores of the lumbar spine (L1L4) or total evaluable vertebrae (if fewer than L1L4); or femoral neck ≤ 2.5 History of vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis; Diagnosed with any condition that will affect bone metabolism</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Japanese</keyword>
</DOC>